Purpose of Review There has been a decline in mortality associated with upper gastrointestinal (UGI) hemorrhage as the use of urgent endoscopy has increased. This review will examine endoscopic risk stratification of non-variceal UGI bleeding (e.g., ulcers, Dieulafoy lesions, and Mallory-Weiss tears), including the use of the Doppler endoscopic probe (DEP). Recent Findings Prospective studies evaluating the use of DEP in non-variceal UGI hemorrhage showed that lesions with high-risk stigmata of recent hemorrhage (SRH) have a higher rate of a positive DEP signal compared to those with intermediate-risk SRH. Additionally, lesions with a persistently positive DEP signal after endoscopic hemostasis were seen with high-risk SRH and had a higher 30-day rebleeding rate. Summary Residual arterial blood flow underneath ulcers is a significant risk factor for rebleeding. However, if more endoscopic treatment is applied, clinical outcomes for patients with severe non-variceal UGI hemorrhage are improved, as documented by a recent CURE Hemostasis randomized controlled trial (RCT).
Introduction
Upper gastrointestinal (UGI) bleeding continues to be a significant health and economic burden. Over the past two decades, there has been a decline in hospitalization for non-variceal UGI hemorrhage, as well as a reduction in non-variceal UGI bleeding-associated mortality. Concurrently, there has been an increase in the rate of in-hospital upper endoscopy-including early endoscopy-and endoscopic therapy [1] . Peptic ulcers are the most common cause of non-variceal UGI hemorrhage [2] . A number of techniques are available to treat bleeding non-variceal UGI lesions. However, it has been difficult to demonstrate a mortality improvement; thus, other clinical outcomes-primary hemostasis rate, rebleed rate, length of hospital stay, need for red blood cell (RBC) transfusions, and rate of angiographic embolization or surgery-are used to assess a particular intervention's effect.
This review will examine endoscopic risk stratification of non-variceal UGI bleeding (e.g., ulcers, Dieulafoy lesions, and Mallory-Weiss tears), including the use of the Doppler endoscopic probe.
Endoscopic Approach Preparation
Patients with severe, active hemorrhage (i.e., a high-volume bloody gastric lavage or ongoing hematemesis, melena, or hematochezia) should undergo emergency endoscopy soon after medical resuscitation, usually in the intensive care unit (ICU). Hemodynamically stable patients can undergo endoscopy often in the endoscopy unit rather than the ICU. For UGI bleeding, therapeutic single-or double-channel endoscopes with large-diameter suction channels are especially useful to This article is part of the Topical Collection on Stomach and Duodenum * Kevin A. Ghassemi kghassemi@mednet.ucla.edu allow quick removal of fresh blood and clots from the GI tract during endoscopy. Additionally, a water pump can be used to target irrigate lesions through the accessory channel and dilute blood for suctioning. Patients at high risk of rebleeding without endoscopic treatment are those with active arterial bleeding treated medically (90% rebleed rate), a NBVV (50%), or an adherent clot (33%) [5] . These patients, and those with the intermediate-risk stigmata of oozing bleeding [6] , benefit from endoscopic hemostasis, whereas low-risk patients with a flat spot alone or clean ulcer base do not, according to past GI clinical guidelines [5, 7] .
Endoscopic Evaluation and Risk Stratification

Doppler Endoscopic Probe
The Doppler endoscopic probe ( Fig. 1 ) for detecting arterial blood flow during GI endoscopy was first described in 1982 [8] . Since then, the Doppler endoscopic probe (DEP) for emergency use has been simplified, and how to use it is easy to teach to GI endoscopists [4•] . The DEP can be passed through the working channel of any diagnostic or therapeutic endoscope. The technique has been most commonly described in the evaluation of bleeding ulcers, but any GI lesion can be interrogated. The base of the ulcer should first be flushed with water to remove any exudate. The DEP tip is applied to the ulcer base with light pressure and at multiple points, including immediately adjacent to any endoscopic SRH. The direction of the artery (location relative to the stigmata) and the depth can be determined with the DEP. The artery detected by Doppler moves away from the visual SRH in a straight line. For non-variceal lesions (such as ulcers, Dieulafoy lesions, or Mallory-Weiss tears), the blood flow detected is arterial and not venous. A positive DEP signal is defined as a repetitive and similar visual spiking waveform (or audible "swish-swish" sound) of at least three consecutive cycles, indicating pulsatile blood [4•, 9] .
Although the DEP does not provide direct hemostasis, its value comes from its ability to help predict both the risk of rebleeding and success of endoscopic treatment. This has been shown in several prospective studies of patients with peptic ulcer bleeding, two of which we describe here in detail. In a study of 52 patients undergoing DEP, 23 underwent endoscopic therapy. Twelve patients had a positive DEP signal prior to endoscopic therapy. Of these patients, 9 (75%) were converted to a negative DEP signal after therapy. All three patients with a persistent DEP-positive signal rebled within 30 days compared to only one patient (11%) whose ulcer had been converted to a DEP-negative signal [10] . In a more recent study, 163 patients with severe peptic ulcer bleeding underwent DEP evaluation during urgent endoscopy. Patients with major SRH (active arterial bleeding, nonbleeding visible vessel, adherent clot) had a significantly higher DEP-positive rate than intermediate SRH (oozing alone or flat spot alone) (87 vs. 42%). After standard, visually guided endoscopic hemostasis with either thermal probe or hemoclip (with or without epinephrine pre-injection), there was a significantly higher residual DEP-positive signal in patients with major SRH vs. intermediate SRH (27 vs. 14%). None of the patients with oozing alone had a positive DEP signal after standard endoscopic hemostasis. The 30-day rebleed rate was 29% in patients with pulsatile bleeding ulcers and 0% in the oozing ulcer group [4•] . In this prospective cohort study, rebleeding occurred in four of five (80%) patients who had residual arterial blood flow after visually guided hemostasis of a spurting ulcer and were treated medically according to current standard of care recommendations. Results of a recent randomized controlled trial (RCT) evaluating the use of DEP in non-variceal UGI hemorrhage-including peptic ulcers, Dieulafoy lesions, and Mallory-Weiss Fig. 1 a A picture of the VTI Doppler endoscopic control unit and an endoscopic catheter. b A diagram of an ulcer base with an invisible artery underneath that can be located by the Doppler endoscopic probe as it courses in the ulcer base. The ear indicates that an auditory sound results as a "swish, swish" for the artery tears-reported significantly higher 30-day rates of rebleeding, major complications, and surgery in the standard therapy group compared with those in the DEP-assisted treatment group [11] . The DEP-assisted hemostasis was safe. These results indicate that residual arterial blood flow underneath ulcers is a significant risk factor for rebleeding. However, if more endoscopic treatment is applied (as in this RCT), clinical outcomes for patients with severe non-variceal UGI hemorrhage are improved.
Hemostasis: Standard Treatments
Thermal contact probes-such as heater, bipolar, and multipolar probe-have been the mainstay of endoscopic hemostasis for decades. These probes affect hemostasis through two mechanisms: tamponade of a blood vessel and interruption of blood flow underlying the SRH, and application of thermal energy to seal the underlying vessel, known as coaptive coagulation. They can be used for a variety of bleeding lesions, including peptic ulcers, Mallory-Weiss tears, and Dieulafoy lesions as major non-variceal UGI (NVUGI) hemorrhage and also less severe GI bleeding from vascular ectasias. The power setting for treating these lesions is low, ranging between 12 and 15 W, and the duration of energy application and amount of pressure applied depend on the depth and size of the vessel being treated [5, 12] . In the laboratory, arteries up to about 1.5 mm in diameter could be coactively closed with thermal probes by applying firm tamponade to reduce arterial blood flow and by slowly applying 100-120 J at low-power settings. The larger thermal probes (10-French size) coagulate larger, deeper arteries more effectively than smaller ones (7-French), because tamponade is more effective and the coagulation zone is larger [12, 13] . For larger vessels, like peptic ulcers, or Dieulafoy lesions, firm pressure and slow coagulation for 8-10 s in more than one tamponade position on either side of the SRH is usually sufficient. Smaller, superficial vessels, such as vascular ectasias, can be treated with lighter pressure for 1-2 s and low-power setting of 12 W. The lowerpower setting is appropriate for thinner wall structure such as the small intestine and right colon, whereas higher-power setting can be used more safely in other areas. The main risk of using a thermal probe is perforation with excessive application of coagulation or pressure, especially in acute or non-fibrotic lesions. Thermal probes also cause a coagulation injury, which can increase the size and depth of ulcers, and may increase the risk of delayed bleeding, particularly in patients with a coagulopathy [12] [13] [14] .
Injection therapy is performed with a sclerotherapy needle to inject epinephrine, diluted to a concentration of 1:10,000 or 1:20,000, submucosally into or around the bleeding site or in the ulcer base around the SRH. Typically, four injections, each 1 cm 3 in volume, are injected around the SRH. This technique is widely available, relatively inexpensive, and safe for use in patients with a coagulopathy. However, it is not as effective for definitive hemostasis as thermal coagulation or endoscopic clips, and typically, it is combined with one of these other two modalities [15] [16] [17] [18] .
Endoscopic clips (also known as hemoclips), which are passed through the endoscope suction channel, can apply mechanical pressure to the bleeding artery and/or the underlying vessel. They offer comparable efficacy to thermal probes in achieving definitive hemostasis [19] . By not causing thermal damage, hemoclips are especially useful in patients with malnutrition or coagulopathy. But they can be difficult or impossible to deploy because of lesion location (such as the posterior bulb of the duodenum) or ulcer base firmness (degree of fibrosis). After DEP localization of the artery underlying the SRH, we recommend hemoclipping on either side of the SRH to occlude the artery and provide definitive hemostasis (Fig. 2) . This can be done with or without pre-injection with epinephrine.
Argon plasma coagulation (APC) uses ionized argon gas to transfer energy to target tissue. A grounding pad is required because it uses a monopolar current. In the UGI tract, it has been used to treat superficial bleeding or sites for potential bleeding, such as vascular ectasias and gastric antral vascular ectasia (GAVE, watermelon stomach) [20] . With superficial coagulation (≤1 mm) and no tamponade capability, there is less efficacy for hemostasis of ulcers with major stigmata of hemorrhage (SRH) and larger or deeper underlying arteries.
Conclusion
While standard endoscopic treatments are effective at providing definitive hemostasis for non-variceal UGI bleeding lesions, there is room for improvement. The DEP has proven Fig. 2 Once the artery is localized under and out from the stigmata such as non-bleeding visible vessel, hemoclips can be accurately placed on either side of the stigma to obliterate the underlying arterial blood flow to be a valuable risk stratification tool, and can serve as a guide to determine whether further treatment is needed after visually guided initial hemostasis is achieved. With major SRH, residual arterial blood flow is common with standard visually guided hemostasis. A recent RCT has reported that DEP-guided treatment is safe and improves clinical outcomes (rebleeding, surgery, complications) compared to standard hemostasis of NVUGI hemorrhage.
